Notably, we provide evidence that patients who experience more profound and longer responses to EGFR blockade preferentially develop EGFR ECD mutations, while RAS mutations emerge more frequently in patients with limited tumour shrinkage and shorter PFS. The gene discussed is EGFR; the disease is neoplasm.